Literature DB >> 15709550

Is the use of specialized nutritional formulations a cost-effective strategy? A national database evaluation.

Adrien Strickland1, Anita Brogan, Janis Krauss, Robert Martindale, Gail Cresci.   

Abstract

BACKGROUND: We apply currently published clinical outcomes data to length of stay and hospital cost to determine the potential economic benefit associated with the use of specialized nutritional formulations in elective surgical, trauma, and medical patients. Although the use of immune-modulating formulations has repeatedly shown favorable clinical outcomes, including decreased complications (both infectious and noninfectious), length of stay (both ICU and total days), and ventilator days, the cost-effectiveness of nutritional modulation of the immune response in a US-based population has not previously been explored.
METHODS: Data for the current study were obtained from a large national database with 126 member hospitals and data from over 1 million patients. Data extracted from the database included patient type (surgical, medical, and trauma) and subservice, whether the hospital stay was "complicated" or "uncomplicated" (as determined by diagnosis-related groups and International Classification of Diseases, Ninth Revision coding), mean length of stay, mean cost, and incremental cost per complication experienced. The clinical outcomes measures from 3 major peer-reviewed studies were then applied to the cost data in order to determine the cost savings associated with the use of specialized nutritional formulations in each of the patient populations. Additionally, cost data were segmented by region of the United States (New England, mid-Atlantic, South, Midwest, Southwest, and West) and by primary focus of the health care facility (academic, indigent care, large community) to enable more meaningful cost comparisons.
RESULTS: For the medical patient population, according to the published rate of 51% decrease in risk of infectious complications and a decreased length of hospital stay of 9.7 days, net cost savings (after accounting for the increased costs of administering immune modulating formula) is $2066. The same calculations were done for surgical and trauma patients, with $688 and $308 net cost savings per patient, respectively. These figures assume a base infection rate of 5%. Expected cost savings vary markedly for deviations in base infection rate and slightly for differences in facility type or region of the country.
CONCLUSIONS: This study demonstrates that specialized nutritional formulations are a cost-effective way for hospitals to improve clinical outcomes while reducing resource consumption and total cost. These benefits are observable in all patient types, all facility types, and all regions of the United States.

Entities:  

Mesh:

Year:  2005        PMID: 15709550     DOI: 10.1177/01486071050290S1S81

Source DB:  PubMed          Journal:  JPEN J Parenter Enteral Nutr        ISSN: 0148-6071            Impact factor:   4.016


  10 in total

1.  Substitution of standard soybean oil with olive oil-based lipid emulsion in parenteral nutrition: comparison of vascular, metabolic, and inflammatory effects.

Authors:  Joselita Siqueira; Dawn Smiley; Christopher Newton; Ngoc-Anh Le; Aidar R Gosmanov; Ronnie Spiegelman; Limin Peng; Samantha J Osteen; Dean P Jones; Arshed A Quyyumi; Thomas R Ziegler; Guillermo E Umpierrez
Journal:  J Clin Endocrinol Metab       Date:  2011-08-10       Impact factor: 5.958

2.  Postsurgical infections are reduced with specialized nutrition support.

Authors:  Dan L Waitzberg; Hideaki Saito; Lindsay D Plank; Glyn G Jamieson; Palepu Jagannath; Tsann-Long Hwang; Juan M Mijares; David Bihari
Journal:  World J Surg       Date:  2006-08       Impact factor: 3.352

3.  A double-blind, randomized clinical trial comparing soybean oil-based versus olive oil-based lipid emulsions in adult medical-surgical intensive care unit patients requiring parenteral nutrition.

Authors:  Guillermo E Umpierrez; Ronnie Spiegelman; Vivian Zhao; Dawn D Smiley; Ingrid Pinzon; Daniel P Griffith; Limin Peng; Timothy Morris; Menghua Luo; Hermes Garcia; Christopher Thomas; Christopher A Newton; Thomas R Ziegler
Journal:  Crit Care Med       Date:  2012-06       Impact factor: 7.598

4.  Immunonutrition for patients undergoing elective surgery for gastrointestinal cancer: impact on hospital costs.

Authors:  Josephine A Mauskopf; Sean D Candrilli; Hélène Chevrou-Séverac; Juan B Ochoa
Journal:  World J Surg Oncol       Date:  2012-07-06       Impact factor: 2.754

5.  Early enteral nutrition in critical illness: a full economic analysis using US costs.

Authors:  Gordon S Doig; Hélène Chevrou-Séverac; Fiona Simpson
Journal:  Clinicoecon Outcomes Res       Date:  2013-08-23

Review 6.  Should perioperative immunonutrition for elective surgery be the current standard of care?

Authors:  Shishira Bharadwaj; Brandon Trivax; Parul Tandon; Bilal Alkam; Ibrahim Hanouneh; Ezra Steiger
Journal:  Gastroenterol Rep (Oxf)       Date:  2016-04-14

7.  Healthcare Resource Utilization and Cost Comparisons of High-Protein Enteral Nutrition Formulas Used in Critically Ill Patients.

Authors:  Matthew C Bozeman; Laura L Schott; Amarsinh M Desai; Mary K Miranowski; Dorothy L Baumer; Cynthia C Lowen; Zhun Cao; Krysmaru Araujo Torres
Journal:  J Health Econ Outcomes Res       Date:  2022-07-01

8.  Prevention and treatment of urinary tract infection with probiotics: Review and research perspective.

Authors:  D Borchert; L Sheridan; A Papatsoris; Z Faruquz; J M Barua; I Junaid; Y Pati; F Chinegwundoh; N Buchholz
Journal:  Indian J Urol       Date:  2008-04

9.  Health economic analyses in medical nutrition: a systematic literature review.

Authors:  Stefan Walzer; Daniel Droeschel; Mark Nuijten; Hélène Chevrou-Séverac
Journal:  Clinicoecon Outcomes Res       Date:  2014-03-10

Review 10.  Health economics evidence for medical nutrition: are these interventions value for money in integrated care?

Authors:  Stefan Walzer; Daniel Droeschel; Mark Nuijten; Hélène Chevrou-Séverac
Journal:  Clinicoecon Outcomes Res       Date:  2014-05-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.